Izumi K M
Department of Microbiology, Harvard Medical School and Medicine, Brigham and Women's Hospital, 857 Channing Laboratory, 181 Longwood Ave, Boston, MA 02115, USA.
Semin Cancer Biol. 2001 Dec;11(6):407-14. doi: 10.1006/scbi.2001.0407.
Epstein-Barr virus (EBV) is able to infect primary B-lymphocytes but usually does not proceed to replicate more virions. Instead, EBV persists as an incomplete virus and expresses 12 gene products that transform the growth of these cells into continuously proliferating lymphoblastoid cell lines. Because EBV is associated with several human malignancies, there is intense interest in delineating the molecular functions of these EBV gene products in transformation. This review focuses on the recombinant EBV technologies that have been developed to introduce specific mutations into EBV and test the functions of these EBV genes in primary B-lymphocyte growth transformation.
爱泼斯坦-巴尔病毒(EBV)能够感染原代B淋巴细胞,但通常不会继续复制更多病毒颗粒。相反,EBV以一种不完全病毒的形式持续存在,并表达12种基因产物,这些产物将这些细胞的生长转化为持续增殖的淋巴母细胞系。由于EBV与多种人类恶性肿瘤相关,因此人们对阐明这些EBV基因产物在转化过程中的分子功能有着浓厚的兴趣。本综述重点关注已开发的重组EBV技术,这些技术用于将特定突变引入EBV,并测试这些EBV基因在原代B淋巴细胞生长转化中的功能。